<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0005110'>Atrial fibrillation</z:hpo> (AF) is a <z:hpo ids='HP_0011675'>cardiac arrhythmia</z:hpo> associated with significant morbidity and mortality, affecting more than 3 million people in the United States and 1-2% of the population worldwide </plain></SENT>
<SENT sid="1" pm="."><plain>Its estimated prevalence is expected to double within the next 50 years </plain></SENT>
<SENT sid="2" pm="."><plain>During the past decade, there have been significant advances in the treatment of AF </plain></SENT>
<SENT sid="3" pm="."><plain>Studies have demonstrated that a rate control strategy, with a target resting heart rate between 80 and 100 beats/minute, is recommended over rhythm control in the vast majority of patients </plain></SENT>
<SENT sid="4" pm="."><plain>The CHA2 DS2 ≥ (<z:hpo ids='HP_0001635'>congestive heart failure</z:hpo>, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, age ≥ 65 yrs, <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo>, <z:hpo ids='HP_0001297'>stroke</z:hpo> or <z:hpo ids='HP_0002326'>transient ischemic attack</z:hpo>, <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular disease</z:e>, female gender) scoring system is a potentially useful <z:hpo ids='HP_0001297'>stroke</z:hpo> risk stratification tool that incorporates additional risk factors to the commonly used CHADS2 (<z:hpo ids='HP_0001635'>congestive heart failure</z:hpo>, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, age ≥ 75 years, <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo>, <z:hpo ids='HP_0001297'>stroke</z:hpo> <z:hpo ids='HP_0002326'>transient ischemic attack</z:hpo>) scoring tool </plain></SENT>
<SENT sid="5" pm="."><plain>Similarly, a convenient scheme, termed HAS-BLED (<z:hpo ids='HP_0000822'>hypertension</z:hpo>, abnormal renal/liver function, <z:hpo ids='HP_0001297'>stroke</z:hpo>, <z:mp ids='MP_0001914'>bleeding</z:mp> history or predisposition, labile international normalized ratio, elderly, drugs/alcohol concomitantly), to assess <z:mp ids='MP_0001914'>bleeding</z:mp> risk has emerged that may be useful in select patients </plain></SENT>
<SENT sid="6" pm="."><plain>Furthermore, new antithrombotic strategies have been developed as potential alternatives to <z:chebi fb="8" ids="10033">warfarin</z:chebi>, including dual-antiplatelet therapy with <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> plus aspirin and the development of new oral <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> such as dabigatran, rivaroxaban, and apixaban </plain></SENT>
<SENT sid="7" pm="."><plain>Vernakalant has emerged as another potential option for pharmacologic conversion of AF, whereas recent trials have better defined the role of <z:chebi fb="0" ids="50659">dronedarone</z:chebi> in the maintenance of sinus rhythm </plain></SENT>
<SENT sid="8" pm="."><plain>Finally, catheter ablation represents another alternative to manage AF, whereas upstream therapy with inhibitors of the renin-angiotensin-<z:chebi fb="0" ids="27584,30834">aldosterone</z:chebi> system, <z:chebi fb="0" ids="35664">statins</z:chebi>, and <z:chebi fb="7" ids="26208">polyunsaturated fatty acids</z:chebi> could potentially prevent the occurrence of AF </plain></SENT>
<SENT sid="9" pm="."><plain>Despite substantial progress in the management of AF, significant uncertainty surrounds the optimal treatment of this condition </plain></SENT>
</text></document>